2. Search Result
Search Result
Results for "

RAP-1

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Peptides

3

Antibodies

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-126133
    AM-001

    		Ras Cardiovascular Disease Others
    AM-001 is a non-competitive inhibitor of Epac1 that blocks the activation of Rap1, a downstream effector of Epac1, in cultured cells. AM-001 can be used in heart disease-related research [1].
    AM-001
  • HY-117958
    HJC0197
    1 Publications Verification

    		 Ras Cardiovascular Disease Metabolic Disease Cancer
    HJC0197 is a potent Epac1 (exchange protein directly activated by cAMP 1) and Epac2 (IC50=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 inhibits Epac1-mediated Rap1-GDP exchange activity at 25 μM in the presence of equal concentration of cAMP [1].
    HJC0197
  • HY-169295
    RAP 1

    		Biochemical Assay Reagents Others
    RAP 1 is a reactive affinity probe (RAP) that selectively labels SLC6A8 in the presence of guanine alanine (GPA). RAP 1 can be used as a chemical probe for identifying and studying potential drug binding sites on SLC6A8 [1].
    RAP 1
  • HY-RS11652
    RAP1A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RAP1A Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RAP1A Human Pre-designed siRNA Set A
    RAP1A Human Pre-designed siRNA Set A
  • HY-RS11653
    RAP1B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RAP1B Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RAP1B Human Pre-designed siRNA Set A
    RAP1B Human Pre-designed siRNA Set A
  • HY-RS11654
    RAP1GAP Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RAP1GAP Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1GAP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RAP1GAP Human Pre-designed siRNA Set A
    RAP1GAP Human Pre-designed siRNA Set A
  • HY-RS11655
    RAP1GAP2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RAP1GAP2 Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1GAP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RAP1GAP2 Human Pre-designed siRNA Set A
    RAP1GAP2 Human Pre-designed siRNA Set A
  • HY-RS11656
    RAP1GDS1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RAP1GDS1 Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1GDS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RAP1GDS1 Human Pre-designed siRNA Set A
    RAP1GDS1 Human Pre-designed siRNA Set A
  • HY-RS02389
    CDK5RAP1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CDK5RAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5RAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDK5RAP1 Human Pre-designed siRNA Set A
    CDK5RAP1 Human Pre-designed siRNA Set A
  • HY-116312
    8-CPT-2'-O-Me-cAMP

    		Ras Cardiovascular Disease
    8-CPT-2'-O-Me-cAMP is a Rap1 activator. 8-CPT-2'-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration [1].
    8-CPT-2'-O-Me-cAMP
  • HY-P10038
    mP6

    Myr-FEEERA-OH

    		 Integrin Infection
    mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells [1].
    mP6
  • HY-107543
    8-CPT-2Me-cAMP sodium

    		Ras Others
    8-CPT-2Me-cAMP sodium is a selective activator of exchange proteins activated by cAMP (Epac), the cAMP sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50> 10 μM) [1]. 8-CPT-2Me-cAMP sodium stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro .
    8-CPT-2Me-cAMP sodium
  • HY-132276
    PtdIns-(3,4,5)-P3-biotin sodium

    		Others Others
    PtdIns-(3,4,5)-P3-biotin sodium is a Biotin-labeled PtdIns-(3,4,5)-P3 (PI(3,4,5)P3). PI(3,4,5)P3 is a substrate of nuclear phosphatidylinositol 5-phosphatase (PIP5Pase). PI(3,4,5)P3 binds to the N-terminus of RAP1 (repressor activator protein 1) and controls its DNA binding activity [1].
    PtdIns-(3,4,5)-P3-biotin sodium
  • HY-12369
    GGTI-2133

    		Others Inflammation/Immunology
    GGTI-2133 is an inhibitor for geranylgeranyltransferase I (GGTase-I) with an IC50 of 38 nM. GGTI-2133 inhibits the geranylation of Rap-1A with an IC50 of 10 μM [1].
    GGTI-2133
  • HY-12369A
    GGTI-2133 TFA

    		Others Inflammation/Immunology
    GGTI-2133 TFA is the TFA salt form of GGTI-2133 (HY-12369). GGTI-2133 TFA is an inhibitor for geranylgeranyltransferase I (GGTase-I) with an IC50 of 38 nM. GGTI-2133 TFA inhibits the geranylation of Rap-1A with an IC50 of 10 μM [1].
    GGTI-2133 TFA
  • HY-15871
    GGTI298 Trifluoroacetate
    3 Publications Verification

    		 Apoptosis Cancer
    GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 μM; little effect on Ha-Ras with IC50 of >20 μM.
    GGTI298 Trifluoroacetate
  • HY-100876
    GGTI298

    		Apoptosis Cancer
    GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC50 values of 3 and > 20 μM in vivo, respectively.
    GGTI298
  • HY-123242
    FTI-2153

    		Farnesyl Transferase Cancer
    FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC50 of 1.4 nM. FTI-2153 is >3000-fold more potent at blocking H-Ras (IC50, 10 nM) than Rap1A processing. Anti-cancer activity [1].
    FTI-2153
  • HY-123242A
    FTI-2153 TFA

    		Farnesyl Transferase Cancer
    FTI-2153 TFA is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC50 of 1.4 nM. FTI-2153 TFA is >3000-fold more potent at blocking H-Ras (IC50, 10 nM) than Rap1A processing. Anti-cancer activity [1].
    FTI-2153 TFA
  • HY-120271
    GGTI-297

    		Ras Cancer
    GGTI-297 is a geranylgeranyl transferase I (GGTase-1) inhibitor with IC50 values of 56 nM and 203 nM for GGTase-1 and fanesyl transferase (FTase), respectively. GGTI-297 inhibits the processing of the geranylgeranylated protein Rap1A without affecting the farnesylated protein H-Ras [1] .
    GGTI-297
  • HY-120229
    GGTI-2147

    		Others Neurological Disease
    GGTI-2147 is a potent GGTase I inhibitor. GGTI-2147 blocks geranyl-geranylation of Rap1A and reduces the activity of Rac1 (one of substrates for GGTI) and ameliorates the OGD/R-induced neuronal apoptosis.GGTI-2147 can be used for neurodevelopmental disorders research, such as autism, depression, and schizophrenia [1].
    GGTI-2147
  • HY-117935
    GGTI-286 hydrochloride

    		Ras Cancer
    GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM [1] .
    GGTI-286 hydrochloride
  • HY-115489
    GGTI-286

    		Ras Cancer
    GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM [1] .
    GGTI-286
  • HY-115489A
    GGTI-286 TFA

    		Others Cancer
    GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM [1] .
    GGTI-286 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: